Although point mutations of the p16 gene are rare in head and neck cancers, alternative mechanisms for the elimination of the p16 function, including homozygous deletions or methylation of the 5-CpG promoter region of p16, are frequently identified [21]. Here, CDKN2A is linked to head and neck cancer.